Alkermes to hive off oncology business

Alkermes to hive off oncology business

Source: 
Pharma Letter
snippet: 

Ireland-incorporated biotech Alkermes’ (Nasdaq: ALKS) shares closed up 3.5% at $24.06 yesterday, as it pleased investors when it revealed that it is to explore separating its commercial-stage neuroscience business and development-stage oncology business.